Cardigan Health: Degenerative Myelopathy
Degenerative Myelopathy is a progressive neurological disease that affects many dog breeds including Cardigan Welsh Corgis. The purpose of this study is to determine definitive diagnoses of Cardigans with progressive spinal cord disease.
All dogs that develop DM will eventually become completely paralyzed and at this point there is no known treatment. In 2008, the University of Missouri developed a genetic test that can predict whether or not a dog is “at risk” for developing the disease. So far it appears that the incidence of this gene is relatively low in Cardigans. The most recent statistics from OFA state that of the 503 Cardigans tested, 50% are clear, 36% are carriers and 13% are at risk.
Not every dog that is “at risk” develops clinical DM and there are other neurological diseases like intervertebral disk disease that can be mistaken for it. DM can only be definitively confirmed by microscopic examination of spinal cord samples collected during a necropsy. Although there have been a number of suspected cases of DM in Cardigans, very few have been confirmed.
Please contact Barbara Merickel DVM, CardiganHealth@cardigancorgis.com if you have a dog that could be included. You and your veterinarian will need to complete a medical history/physical findings form. We will assist you in arranging for a necropsy (autopsy) which will need to be performed shortly after your dog had died or been euthanized. If you wish, your dog can be cremated with the ashes returned to you. The tissue samples will be sent to Dr. Joan Coates at the University of Missouri.
This study is open to all Cardigan Welsh Corgis, not limited to CWCCA Members.
Additional information and sample submission forms are available at this link.
Mizzou Study for the Treatment of DM
CWCCA Degenerative Myelopathy Study
Published July, 2017
COLUMBIA, Mo. – In 2009, Joan Coates, a veterinary neurologist, along with other researchers at the University of Missouri and the Broad Institute at MIT/Harvard, found a genetic link between degenerative myelopathy (DM) in dogs and amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease in people. Now, MU researchers Coates and Michael Garcia, an associate professor in the Division of Biological Sciences, have found that a biomarker test that helps diagnose ALS also can assist with determining a diagnosis for degenerative myelopathy.
Coates is seeking clinical trial participants to evaluate a treatment for canine DM.
Coates is conducting clinical trial research for treatment of DM. The goals of the therapies being tested is to slow the progression of neurologic signs of DM and improve quality of life. These therapies are in collaborations with other ALS researchers and funded by the ALS Association and National Institutes of Health. The clinical trials are taking place at the MU Veterinary Health Center (VHC) Small Animal Hospital. To inquire about enrolling a dog, contact Coates at firstname.lastname@example.org.
Currently there are two ongoing treatment studies at the University of Missouri. Below are the inclusion criteria. Based on disease suspicion and early disease stage, the study may be able to pay for the MRI screening. The diagnostic testing highlighted are to be done by the primary care veterinarian prior to referral to the University of Missouri because we need to make sure the dog is in good health.
Both studies will be blinded with few dogs randomly assigned to a control group. In other words, the study candidate has a 70-80% chance of getting the treatment. Once the dog is selected as a candidate and assigned to a study, the specific details of the study will be thoroughly discussed.
Slowly progressive loss of coordination over 1-3 months, no signs of waxing or waning, and the owners do not perceive their dog to be in discomfort
EARLY DISEASE: Progressive asymmetric general proprioceptive ataxia that is considered mild. Breeds Included
Diagnostic Testing (Performed by a board-certified veterinary neurologist: www.acvim.org)
Treatments and Follow-up Testing
An informed consent will be signed by the owner and Dr. Coates. The owner must be compliant and return to the MU VHC as directed based on study protocol
Following death or at time of euthanasia, the dog will need to be brought to MU VHC for necropsy. A histopathologic confirmation of DM is required.